499 related articles for article (PubMed ID: 23726392)
1. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.
Hu Y; Lu S; Song Z; Wang W; Hao P; Li J; Zhang X; Yen HL; Shi B; Li T; Guan W; Xu L; Liu Y; Wang S; Zhang X; Tian D; Zhu Z; He J; Huang K; Chen H; Zheng L; Li X; Ping J; Kang B; Xi X; Zha L; Li Y; Zhang Z; Peiris M; Yuan Z
Lancet; 2013 Jun; 381(9885):2273-9. PubMed ID: 23726392
[TBL] [Abstract][Full Text] [Related]
2. Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection.
Shen Z; Chen Z; Li X; Xu L; Guan W; Cao Y; Hu Y; Zhang J
Clin Microbiol Infect; 2014 Aug; 20(8):O493-500. PubMed ID: 24350809
[TBL] [Abstract][Full Text] [Related]
3. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Yen HL; McKimm-Breschkin JL; Choy KT; Wong DD; Cheung PP; Zhou J; Ng IH; Zhu H; Webby RJ; Guan Y; Webster RG; Peiris JS
mBio; 2013 Jul; 4(4):. PubMed ID: 23860768
[TBL] [Abstract][Full Text] [Related]
4. Characterization of viral genomic mutations in novel influenza A (H7N9)-infected patients: the association between oseltamivir-resistant variants and viral shedding duration.
Chen R; Zou Q; Xie G; Yu F; Yang X; Cao L; Huo Z; Zheng S
Virus Genes; 2019 Oct; 55(5):592-599. PubMed ID: 31302878
[TBL] [Abstract][Full Text] [Related]
5. Therapy of H7N9 pneumonia: current perspectives.
Cao B; Hayden FG
Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1123-6. PubMed ID: 24151830
[No Abstract] [Full Text] [Related]
6. Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy.
Piralla A; Gozalo-Margüello M; Fiorina L; Rovida F; Muzzi A; Colombo AA; Alessandrino PE; Baldanti F
J Clin Virol; 2013 Sep; 58(1):132-7. PubMed ID: 23810646
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Zhang Y; Gao H; Liang W; Tang L; Yang Y; Wu X; Yu L; Chen P; Zheng S; Ou H; Li L
BMC Infect Dis; 2016 Feb; 16():76. PubMed ID: 26864456
[TBL] [Abstract][Full Text] [Related]
8. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010.
Meijer A; Jonges M; Abbink F; Ang W; van Beek J; Beersma M; Bloembergen P; Boucher C; Claas E; Donker G; van Gageldonk-Lafeber R; Isken L; de Jong A; Kroes A; Leenders S; van der Lubben M; Mascini E; Niesters B; Oosterheert JJ; Osterhaus A; Riesmeijer R; Riezebos-Brilman A; Schutten M; Sebens F; Stelma F; Swaan C; Timen A; van 't Veen A; van der Vries E; te Wierik M; Koopmans M
Antiviral Res; 2011 Oct; 92(1):81-9. PubMed ID: 21767571
[TBL] [Abstract][Full Text] [Related]
9. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).
Whitley RJ; Boucher CA; Lina B; Nguyen-Van-Tam JS; Osterhaus A; Schutten M; Monto AS
Clin Infect Dis; 2013 May; 56(9):1197-205. PubMed ID: 23307766
[TBL] [Abstract][Full Text] [Related]
10. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors.
Antón A; López-Iglesias AA; Tórtola T; Ruiz-Camps I; Abrisqueta P; Llopart L; Marcos MÁ; Martínez MJ; Tudó G; Bosch F; Pahissa A; de Anta MT; Pumarola T
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):214-9. PubMed ID: 20955912
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
Ison MG; Hui DS; Clezy K; O'Neil BJ; Flynt A; Collis PJ; Simon TJ; Alexander WJ
Antivir Ther; 2013; 18(5):651-61. PubMed ID: 23111657
[TBL] [Abstract][Full Text] [Related]
12. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
[TBL] [Abstract][Full Text] [Related]
13. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
Tamura D; Sugaya N; Ozawa M; Takano R; Ichikawa M; Yamazaki M; Kawakami C; Shimizu H; Uehara R; Kiso M; Kawakami E; Mitamura K; Kawaoka Y
Clin Infect Dis; 2011 Feb; 52(4):432-7. PubMed ID: 21248368
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
15. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C
Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638
[TBL] [Abstract][Full Text] [Related]
16. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
[TBL] [Abstract][Full Text] [Related]
17. [Current anti-influenza virus chemotherapy].
Yoshioka D; Tokimatsu I; Ishii H; Kadota J
Nihon Rinsho; 2010 Sep; 68(9):1679-84. PubMed ID: 20845747
[TBL] [Abstract][Full Text] [Related]
18. Optimizing antiviral therapy for influenza: understanding the evidence.
Ison MG
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):417-25. PubMed ID: 25695406
[TBL] [Abstract][Full Text] [Related]
19. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study.
Chen H; Yuan H; Gao R; Zhang J; Wang D; Xiong Y; Fan G; Yang F; Li X; Zhou J; Zou S; Yang L; Chen T; Dong L; Bo H; Zhao X; Zhang Y; Lan Y; Bai T; Dong J; Li Q; Wang S; Zhang Y; Li H; Gong T; Shi Y; Ni X; Li J; Zhou J; Fan J; Wu J; Zhou X; Hu M; Wan J; Yang W; Li D; Wu G; Feng Z; Gao GF; Wang Y; Jin Q; Liu M; Shu Y
Lancet; 2014 Feb; 383(9918):714-21. PubMed ID: 24507376
[TBL] [Abstract][Full Text] [Related]
20. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
